{"id":831117,"date":"2025-03-28T08:46:08","date_gmt":"2025-03-28T12:46:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-schedules-release-of-full-year-2024-financial-results-and-conference-call\/"},"modified":"2025-03-28T08:46:08","modified_gmt":"2025-03-28T12:46:08","slug":"vivos-therapeutics-schedules-release-of-full-year-2024-financial-results-and-conference-call","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-schedules-release-of-full-year-2024-financial-results-and-conference-call\/","title":{"rendered":"Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call"},"content":{"rendered":"<h2>\nCall Scheduled for Monday, March 31, 2025 at 5:00 pm ET<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">LITTLETON, Colo., March  28, 2025  (GLOBE NEWSWIRE) &#8212; <strong>Vivos Therapeutics, Inc. (\u201cVivos\u201d or the \u201cCompany\u201d) (NASDAQ: VVOS)<\/strong>, a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring in adults and moderate to severe OSA in children ages 6 \u2013 17), today announced it plans to release its full year 2024 financial results after market close on Monday, March 31, 2025. The Company will conduct a conference call at 5:00 p.m. (Eastern Time) on March 31, 2025 to review the results and provide an overview of the Company\u2019s recent milestones and developments.<\/p>\n<p align=\"justify\">To access Vivos\u2019 investor conference call, please dial (800) 717-1738, or for international callers, (646) 307-1865. A replay will be available shortly after the call and can be accessed by dialing (844) 512-2921, or for international callers, (412) 317-6671. The passcode for the replay is 1103883. The replay will be available until April 14, 2025.<\/p>\n<p align=\"justify\">A live webcast of the conference call can be accessed on Vivos\u2019 website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CgQV_sy5A5G011GPNmSsZmqkuRJTJ4H7-KOnsDks9y5mam9eXS_53NqvAid0deUD3IeS3_lpUER1RpNbmH4TwZ3EOur9E2jup6V7w4CJRvFG1cl_p0dHMMtgI-Cj67G6YVKY27WXU7c0SlASo6t-4A==\" rel=\"nofollow\" target=\"_blank\">https:\/\/vivos.com\/investor-relations<\/a>. An online archive of the webcast will be available on the Company\u2019s website for 30 days following the call.<\/p>\n<p>\n        <strong>About Vivos Therapeutics, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults and moderate to severe OSA in children ages 6 \u2013 17. The Vivos Method represents the first clinically effective nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution for treating mild to severe OSA in adults and moderate to severe OSA in children ages 6-17. It has proven effective in approximately 58,000 patients treated worldwide by more than 2,000 trained dentists.<\/p>\n<p align=\"justify\">The Vivos Method includes treatment regimens that employ proprietary CARE appliance therapy and other modalities that alter the size, shape and position of the jaw and soft tissues that comprise a patient\u2019s upper airway and\/or palate. The Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild-to-severe OSA in adults and moderate-to-severe OSA in children ages 6 to 17, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for home sleep testing in adults and children. The Vivos Integrated Practice (VIP) program offers dentists training and other value-added services in connection with using The Vivos Method. Vivos also employs a marketing and distribution model where it collaborates with sleep-treatment providers to offer patients OSA treatment options and help promote sales of its appliances.<\/p>\n<p align=\"justify\">For more information, visit\u00a0www.vivos.com.<\/p>\n<p>\n        <strong>Cautionary Note Regarding Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release, the conference call referred to herein, and statements of the Company\u2019s management made in connection therewith contain \u201cforward-looking statements\u201d (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events. Words such as \u201cmay\u201d, \u201cshould\u201d, \u201cexpects\u201d, \u201cprojects,\u201d \u201cintends\u201d, \u201cplans\u201d, \u201cbelieves\u201d, \u201canticipates\u201d, \u201chopes\u201d, \u201cestimates\u201d, \u201cgoal\u201d and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve significant known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos\u2019 control. Actual results (including the actual future impact of the initiatives and corporate achievements described herein on Vivos\u2019 future revenues and results of operations and the anticipated benefits of the Company\u2019s new marketing and distribution model described herein) may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to: (i) the risk that Vivos may be unable to implement revenue, sales and marketing strategies and other strategies that increase revenues, (ii) the risk that some patients may not achieve the desired results from using Vivos products, (iii) risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea treatment sector; (iv) the risk that Vivos may be unable to secure additional financings on reasonable terms when needed, if at all, or maintain its Nasdaq listing (v) market and other conditions, and (vi) other risk factors described in Vivos\u2019 filings with the Securities and Exchange Commission (\u201cSEC\u201d). Vivos\u2019 filings can be obtained free of charge on the SEC\u2019s website at www.sec.gov. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos\u2019 expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based.<\/p>\n<p>\n        <strong>Vivos Investor Relations and Media Contact:<\/strong><br \/>\n        <br \/>Bradford Amman<br \/>Chief Financial Officer and Investor Relations Contact<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=em7t1MIQmM1B8-fPzmzJhKYwkh-gmTUPFoM3yTbCSzp2_GqIVhQYBf0D1YoeQKao4oKmQQDg1gFG3QL0Bb4Ns9vZZFKh_7v50z_HZDv14iZLGAUungBKdogFZio62blw\" rel=\"nofollow\" target=\"_blank\">investors@vivoslife.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMjUzMSM2ODM4NzU5IzIyMDU4NTM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/Mzg3ODA5MzEtYTliNi00ZDMwLTg4MDUtOGM2YjZmYzE2YTk3LTEyMTc0MDYtMjAyNS0wMy0yOC1lbg==\/tiny\/Vivos-Therapeutics-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Call Scheduled for Monday, March 31, 2025 at 5:00 pm ET LITTLETON, Colo., March 28, 2025 (GLOBE NEWSWIRE) &#8212; Vivos Therapeutics, Inc. (\u201cVivos\u201d or the \u201cCompany\u201d) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring in adults and moderate to severe OSA in children ages 6 \u2013 17), today announced it plans to release its full year 2024 financial results after market close on Monday, March 31, 2025. The Company will conduct a conference call at 5:00 p.m. (Eastern Time) on March 31, 2025 to review the results and provide an overview of the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-schedules-release-of-full-year-2024-financial-results-and-conference-call\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-831117","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-schedules-release-of-full-year-2024-financial-results-and-conference-call\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Call Scheduled for Monday, March 31, 2025 at 5:00 pm ET LITTLETON, Colo., March 28, 2025 (GLOBE NEWSWIRE) &#8212; Vivos Therapeutics, Inc. (\u201cVivos\u201d or the \u201cCompany\u201d) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring in adults and moderate to severe OSA in children ages 6 \u2013 17), today announced it plans to release its full year 2024 financial results after market close on Monday, March 31, 2025. The Company will conduct a conference call at 5:00 p.m. (Eastern Time) on March 31, 2025 to review the results and provide an overview of the &hellip; Continue reading &quot;Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-schedules-release-of-full-year-2024-financial-results-and-conference-call\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-28T12:46:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMjUzMSM2ODM4NzU5IzIyMDU4NTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivos-therapeutics-schedules-release-of-full-year-2024-financial-results-and-conference-call\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivos-therapeutics-schedules-release-of-full-year-2024-financial-results-and-conference-call\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call\",\"datePublished\":\"2025-03-28T12:46:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivos-therapeutics-schedules-release-of-full-year-2024-financial-results-and-conference-call\\\/\"},\"wordCount\":820,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivos-therapeutics-schedules-release-of-full-year-2024-financial-results-and-conference-call\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMjUzMSM2ODM4NzU5IzIyMDU4NTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivos-therapeutics-schedules-release-of-full-year-2024-financial-results-and-conference-call\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivos-therapeutics-schedules-release-of-full-year-2024-financial-results-and-conference-call\\\/\",\"name\":\"Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivos-therapeutics-schedules-release-of-full-year-2024-financial-results-and-conference-call\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivos-therapeutics-schedules-release-of-full-year-2024-financial-results-and-conference-call\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMjUzMSM2ODM4NzU5IzIyMDU4NTM=\",\"datePublished\":\"2025-03-28T12:46:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivos-therapeutics-schedules-release-of-full-year-2024-financial-results-and-conference-call\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivos-therapeutics-schedules-release-of-full-year-2024-financial-results-and-conference-call\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivos-therapeutics-schedules-release-of-full-year-2024-financial-results-and-conference-call\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMjUzMSM2ODM4NzU5IzIyMDU4NTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMjUzMSM2ODM4NzU5IzIyMDU4NTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivos-therapeutics-schedules-release-of-full-year-2024-financial-results-and-conference-call\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-schedules-release-of-full-year-2024-financial-results-and-conference-call\/","og_locale":"en_US","og_type":"article","og_title":"Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call - Market Newsdesk","og_description":"Call Scheduled for Monday, March 31, 2025 at 5:00 pm ET LITTLETON, Colo., March 28, 2025 (GLOBE NEWSWIRE) &#8212; Vivos Therapeutics, Inc. (\u201cVivos\u201d or the \u201cCompany\u201d) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring in adults and moderate to severe OSA in children ages 6 \u2013 17), today announced it plans to release its full year 2024 financial results after market close on Monday, March 31, 2025. The Company will conduct a conference call at 5:00 p.m. (Eastern Time) on March 31, 2025 to review the results and provide an overview of the &hellip; Continue reading \"Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-schedules-release-of-full-year-2024-financial-results-and-conference-call\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-28T12:46:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMjUzMSM2ODM4NzU5IzIyMDU4NTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-schedules-release-of-full-year-2024-financial-results-and-conference-call\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-schedules-release-of-full-year-2024-financial-results-and-conference-call\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call","datePublished":"2025-03-28T12:46:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-schedules-release-of-full-year-2024-financial-results-and-conference-call\/"},"wordCount":820,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-schedules-release-of-full-year-2024-financial-results-and-conference-call\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMjUzMSM2ODM4NzU5IzIyMDU4NTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-schedules-release-of-full-year-2024-financial-results-and-conference-call\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-schedules-release-of-full-year-2024-financial-results-and-conference-call\/","name":"Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-schedules-release-of-full-year-2024-financial-results-and-conference-call\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-schedules-release-of-full-year-2024-financial-results-and-conference-call\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMjUzMSM2ODM4NzU5IzIyMDU4NTM=","datePublished":"2025-03-28T12:46:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-schedules-release-of-full-year-2024-financial-results-and-conference-call\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-schedules-release-of-full-year-2024-financial-results-and-conference-call\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-schedules-release-of-full-year-2024-financial-results-and-conference-call\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMjUzMSM2ODM4NzU5IzIyMDU4NTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMjUzMSM2ODM4NzU5IzIyMDU4NTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-schedules-release-of-full-year-2024-financial-results-and-conference-call\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/831117","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=831117"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/831117\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=831117"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=831117"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=831117"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}